CTP-543

Medical professionals may also email us at AAclinicaltrial_inquiries@concertpharma.com for more information about CTP-543 study participation.

A Phase 3 Study to Evaluate the Efficacy and Safety of CTP-543 in Adult Patients With Moderate to Severe Alopecia Areata

Evaluating the efficacy and safety of CTP-543 in adult patients with moderate to severe alopecia areata.

Status: Not Yet Recruiting
https://clinicaltrials.gov/ct2/show/NCT04518995

Study to Evaluate the Safety and Efficacy of CTP-543 in Adult Patients With Moderate to Severe Alopecia Areata

Evaluating the safety and efficacy of CTP-543 in adult patients with chronic, moderate to severe alopecia areata.

Status: Completed
https://clinicaltrials.gov/ct2/show/NCT03137381

Efficacy and Tolerability Study of Two Dosing Regimens of CTP-543 in Adults With Alopecia Areata

Evaluating the efficacy and tolerability of once-daily versus twice-daily dosing of CTP-543, in adult patients with chronic, moderate to severe alopecia areata

Status: Completed
https://clinicaltrials.gov/ct2/show/NCT03941548

Efficacy and Tolerability Study of Two Dose Regimens of CTP-543 in Adults With Alopecia Areata

Evaluating the efficacy and tolerability of once-daily versus twice-daily dosing of CTP-543, in adult patients with chronic, moderate to severe alopecia areata

Status: Completed
https://clinicaltrials.gov/ct2/show/NCT03811912

Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata

Evaluating long-term safety of CTP-543 and to assessing long-term effects of CTP-543 in adult patients with chronic, moderate-to-severe alopecia areata who completed 24 weeks of treatment in a previous qualifying CTP-543 clinical trial.

Status: Active, Not Recruiting
https://clinicaltrials.gov/ct2/show/NCT03898479

CTP-692

Medical professionals may also email us at CNSclinicaltrial_inquiries@concertpharma.com for more information about CTP-692 study participation.

A Phase 2 Study to Evaluate the Safety and Efficacy of CTP-692 as an Adjunctive Treatment in Adults With Schizophrenia

Evaluating the  safety and efficacy of CTP-692 in patients with schizophrenia on stable antipsychotic medication.

Status: Recruiting
https://clinicaltrials.gov/ct2/show/NCT04158687 

Multiple Ascending Dose Study of CTP-692 in Healthy Volunteers

Assessing in healthy male and female subjects the safety and pharmacokinetic (PK) profiles of 3 dose levels of CTP-692 following 7 days of dosing.

Status: Completed
https://clinicaltrials.gov/ct2/show/NCT03880253

Concert is committed to developing innovative medicines for autoimmune and CNS disorders.

Participation in our clinical trials plays a vital role in helping develop new medicines. While we do not currently offer investigational therapies outside of our clinical trials, you and your physician may determine that enrolling in a trial may be an option for you. For more information about Concert’s ongoing clinical trial programs, please reference the trials listed above.